[1] HOWARD FM, OLOPADE OI. Epidemiology of triple-negative breast cancer: A review[J]. Cancer J, 2021, 27(1): 8. doi: 10.1097/PPO.0000000000000500
[2] YIN L, DUAN JJ, BIAN XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1): 61. doi: 10.1186/s13058-020-01296-5
[3] SUKUMAR J, GAST K, QUIROGA D, et al. Triple-negative breast cancer: promising prognostic biomarkers currently in development[J]. Expert Rev Anticancer Ther, 2021, 21(2): 135. doi: 10.1080/14737140.2021.1840984
[4] SHARMA U, BARWAL TS, KHANDELWAL A, et al. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3[J]. Biochimie, 2021, 182: 99. doi: 10.1016/j.biochi.2020.12.026
[5] RAO DD, VORHIES JS, SENZER N, et al. siRNA vs. shRNA: similarities and differences[J]. Adv Drug Deliv Rev, 2009, 61(9): 746. doi: 10.1016/j.addr.2009.04.004
[6] SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7. doi: 10.3322/caac.21708
[7] 岳成旭, 王文锐, 杨清玲, 等. LncRNA SNHG15通过调控miRNA-451a促进乳腺癌细胞的上皮间质转化研究[J]. 蚌埠医学院学报, 2022, 47(4): 421.
[8] BORRI F, GRANAGLIA A. Pathology of triple negative breast cance[J]. Semin Cancer Biol, 2021, 72: 136. doi: 10.1016/j.semcancer.2020.06.005
[9] AGOSTINETTO E, EIGER D, PUNIE K, et al. Emerging therapeutics for patients with triple-negative breast cancer[J]. CurrOncol Rep, 2021, 23(5): 57.
[10] KUMARI M, KRISHNAMURTHY PT, SOLA P. Targeted drug therapy to overcome chemoresistance in triple-negative breast cancer[J]. Curr Cancer Drug Targets, 2020, 20(8): 559. doi: 10.2174/1568009620666200506110850
[11] JIAO XX, LIN SY, LIAN SX, et al. The inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway[J]. Neoplasma, 2020, 67(4): 834. doi: 10.4149/neo_2020_190805N716
[12] GELAIN A, MORI M, MENEGHETTI F, et al. Signal transducer and activator of transcription protein 3(STAT3): an update on its direct inhibitors as promising anticancer agents[J]. Curr Med Chem, 2019, 26(27): 5165. doi: 10.2174/0929867325666180719122729
[13] SANTONI M, MICCINI F, CIMADAMORE A, et al. An update on investigational therapies that target STAT3 for the treatment of cancer[J]. Expert OpinInvestig Drugs, 2021, 30(3): 245. doi: 10.1080/13543784.2021.1891222
[14] OWEN KL, BROCKWELL NK, PARKER BS. JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression[J]. Cancers(Basel), 2019, 11(12): 2002.
[15] LIU J, LIU L, YAGÜE E, et al. GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation[J]. Breast Cancer Res Treat, 2019, 174(1): 65. doi: 10.1007/s10549-018-5052-z
[16] PARK SK, BYUN WS, LEE S, et al. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction[J]. BiochemPharmacol, 2020, 178: 114053.
[17] KHAN MW, SAADALLA A, EWIDA AH, et al. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer[J]. Cancer ImmunolImmunother, 2018, 67(1): 13. doi: 10.1007/s00262-017-2057-0
[18] DONG J, CHENG XD, ZHANG WD, et al. Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation[J]. J Med Chem, 2021, 64(13): 8884. doi: 10.1021/acs.jmedchem.1c00629